MCID: HML018
MIFTS: 22

Homologous Wasting Disease

Categories: Rare diseases

Aliases & Classifications for Homologous Wasting Disease

MalaCards integrated aliases for Homologous Wasting Disease:

Name: Homologous Wasting Disease 53
Graft-Vs-Host Disease 72

Classifications:



External Ids:

UMLS 72 C0018133

Summaries for Homologous Wasting Disease

MalaCards based summary : Homologous Wasting Disease, is also known as graft-vs-host disease. The drugs Thiotepa and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow.

Related Diseases for Homologous Wasting Disease

Symptoms & Phenotypes for Homologous Wasting Disease

Drugs & Therapeutics for Homologous Wasting Disease

Drugs for Homologous Wasting Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 373)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
2
Lomustine Approved, Investigational Phase 4 13010-47-4 3950
3
Histamine Approved, Investigational Phase 4 51-45-6 774
4
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
5
Promethazine Approved, Investigational Phase 4 60-87-7 4927
6
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
7
Simethicone Approved Phase 4 8050-81-5
8
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Magnesium hydroxide Approved, Investigational Phase 4 1309-42-8
11
Povidone Approved Phase 4 9003-39-8
12
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
13
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
14
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
15
Semustine Experimental, Investigational Phase 4 13909-09-6
16
Treosulfan Investigational Phase 4 299-75-2 9296
17
Histamine Phosphate Phase 4 51-74-1 65513
18 Antiparasitic Agents Phase 4
19 Antiprotozoal Agents Phase 4
20 Neurotransmitter Agents Phase 4
21 Thymoglobulin Phase 4
22 Anti-Allergic Agents Phase 4
23 Central Nervous System Depressants Phase 4
24 Histamine H1 Antagonists Phase 4
25 Histamine Antagonists Phase 4
26 Hypnotics and Sedatives Phase 4
27 Antipruritics Phase 4
28 Sodium Channel Blockers Phase 4
29 Aluminum hydroxide, magnesium hydroxide, drug combination Phase 4
30 Antacids Phase 4
31 Diuretics, Potassium Sparing Phase 4
32 Plasma Substitutes Phase 4
33 Anti-Arrhythmia Agents Phase 4
34 Viscosupplements Phase 4
35 Emollients Phase 4
36 Anti-Ulcer Agents Phase 4
37 Blood Substitutes Phase 4
38 14-alpha Demethylase Inhibitors Phase 4
39 Steroid Synthesis Inhibitors Phase 4
40 Cytochrome P-450 Enzyme Inhibitors Phase 4
41 Lubricant Eye Drops Phase 4
42 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
43 Cytochrome P-450 CYP3A Inhibitors Phase 4
44
Hydroxyitraconazole Phase 4
45
Budesonide Approved Phase 3 51333-22-3 63006 5281004
46
Etanercept Approved, Investigational Phase 3 185243-69-0
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
48
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
49
Carmustine Approved, Investigational Phase 2, Phase 3 154-93-8 2578
50
Hydroxychloroquine Approved Phase 3 118-42-3 3652

Interventional clinical trials:

(show top 50) (show all 802)
# Name Status NCT ID Phase Drugs
1 Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study Unknown status NCT02342145 Phase 4 Basiliximab,;cyclosporine A;Methotrexate;Mycophenolate mofetil
2 A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation. Completed NCT00195481 Phase 4 Rapamune
3 An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor Completed NCT00044720 Phase 4 Rapamune
4 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
5 A Randomized, Open-label and Multicenter Trial Comparing Withdrawal of Steroids or Tacrolimus From Sirolimus-based Immunosuppressive Regimen in de Novo Renal Allograft Recipients Completed NCT00195429 Phase 4 Tacrolimus;Sirolimus;prednisone
6 A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporine Dose Reduction With Cyclosporine Elimination in De Novo Renal Allograft Recipients Receiving Rapamune. Completed NCT00195468 Phase 4 CYCLOSPORINE
7 A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor Completed NCT02660684 Phase 4 Prograf;Methotrexate;Cyclosporine
8 Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis Completed NCT01883180 Phase 4 ATG
9 Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients Completed NCT02968134 Phase 4 Posaconazole
10 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
11 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
12 A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis Recruiting NCT03689465 Phase 4 ATG;CTX;Mycophenolate Mofetil
13 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
14 An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash ("Magic Mouthwash") for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients Recruiting NCT03490396 Phase 4
15 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
16 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
17 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
18 The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye Terminated NCT00553735 Phase 4 Cyclosporine A 0.05%;Arificial Tear
19 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
20 Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation Unknown status NCT00207792 Phase 3 filgrastim
21 The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study Unknown status NCT02506231 Phase 2, Phase 3 Folinic acid;Placebo
22 Extracorporeal Photopheresis for Steroid-refractory Acute GVHD in Children and Young Adults: a Safety and Feasibility Study. Unknown status NCT00179855 Phase 2, Phase 3
23 Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation Unknown status NCT02241018 Phase 2, Phase 3 CD25 monoclonal antibody;calcineurin inhibitors
24 Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
25 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
26 A Phase II/III, Multicenter, Open Label, Randomized Clinical Trial Evaluating ABX-CBL When Compared to Atgam as Second Line Therapy in Patients With Steroid Resistant Acute Graft Versus Host Disease Completed NCT00035880 Phase 2, Phase 3 ABX-CBL
27 Double-blind, Randomised, Placebo-controlled Multicentre Phase III Clinical Study Followed by Open-label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GvHD Completed NCT00887263 Phase 3 Budesonide;Placebo
28 Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease in Paediatric Patients Completed NCT01788501 Phase 2, Phase 3 Tacrolimus;Cyclosporine;Methotrexate
29 An Open-label Extension Study of the Safety of Long-term Administration of Sirolimus (Rapamune™) in Solid Organ Transplant Recipients Completed NCT00037531 Phase 3 Sirolimus (RAPAMUNE)
30 Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease Completed NCT00034645 Phase 3 Posaconazole oral suspension
31 Efficacy and Safety of Orale Budesonide in the Prevention of Acute Gastrointestinal Graft-versus-host Disease Following Allogenic Stem Cell Transplantation Completed NCT00180089 Phase 3 Budesonide
32 Randomized Double-blid Clinical Trial Comparing the Topical Treatment With Clobetasol and Dexamethasone for Oral Lesions of Chronic Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Completed NCT01699412 Phase 3 Clobetasol;Dexamethasone
33 A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids With Mycophenolate Mofetil vs. Corticosteroids With Placebo as Initial Systemic Treatment of Acute Graft-Vs-Host-Disease (BMT CTN #0802) Completed NCT01002742 Phase 3 Mycophenolate Mofetil;Placebo
34 A Phase III, Randomized, Placebo-Controlled, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Oral Beclomethasone 17, 21-Dipropionate (BDP) in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Grade II Graft vs. Host Disease With Gastrointestinal Symptoms Completed NCT00043147 Phase 3 beclomethasone dipropionate;methylprednisolone;prednisone
35 A Randomized, Open Label Study to Evaluate the Effects of a Regimen With Sirolimus,Low Doses Cyclosporine and Steroids vs a Regimen With Sirolimus and Steroids, After an Induction Period With Basiliximab, Sirolimus,Cyclosporine and Steroids in de Novo Renal Transplant Patients. Completed NCT00167947 Phase 3 Cyclosporine;Steroids;Rapamune (Sirolimus)
36 Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation Completed NCT00001561 Phase 3 Myeloma Immunoglobulin Idiotype Vaccine-KLH;GM-CSF
37 A Randomized Open-Label Study Comparing the Efficacy and Safety of Sirolimus Combined With Daclizumab, Mycophenolate and Corticosteroids vs Cyclosporine, Mycophenolate and Corticosteroids in Renal Allograft Recipients Receiving Kidneys From Older Donors Completed NCT00195273 Phase 3 sirolimus;cyclosporine;mycophenolate mofetil;corticosteroids;daclizumab
38 A Randomized, Placebo-Controlled, Multi-Center Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal Graft Vs. Host Disease Completed NCT00233896 Phase 3 Oral beclomethasone dipropionate (drug)
39 GvHD Prophylaxis With ATG-Fresenius S in Allogeneic Stem Cell Transplantation From Matched Unrelated Donors: A Randomized Phase III Multicenter Trial Comparing a Standard GvHD Prophylaxis With Cyclosporine A and Methotrexate With Additional Pretransplant ATG-Fresenius S Completed NCT00655343 Phase 3 ATG-Fresenius S
40 Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo Completed NCT00053976 Phase 3 methylprednisolone;Placebo
41 Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
42 Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease Completed NCT00002456 Phase 3 cyclosporine;methotrexate
43 A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Completed NCT00322101 Phase 3 cyclophosphamide;mycophenolate mofetil;busulfan;cyclosporine;fludarabine phosphate;tacrolimus;methotrexate
44 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
45 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies Completed NCT01188798 Phase 3 Methotrexate;Pentostatin
46 A Phase III, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal(Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Steroid Refractory Acute GVHD Completed NCT00366145 Phase 3
47 A Phase III Study to Determine Efficacy and Safety of Low-Dose Glucocorticoids for Initial Treatment of Acute Graft-versus-Host Disease Completed NCT00929695 Phase 3 prednisone;methylprednisolone
48 The Use of Etanercept (Enbrel) as Sole Treatment for Grade I Acute Graft Versus Host Disease Completed NCT00726375 Phase 3 Etanercept (Enbrel)
49 A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus Plus Prednisone and Sirolimus/Calcineurin Inhibitor Plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease (BMT CTN Protocol #0801) Completed NCT01106833 Phase 2, Phase 3 Sirolimus + calcineurin inhibitor + prednisone;Sirolimus + prednisone
50 A Prospective Randomized Study Comparing Rapamune and Tacrolimus vs. Cyclosporine and Methotrexate as Immune Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation, Using HLA-A, -B, -DRβ1 Identical Related or Unrelated Donors. A Nordic Multicenter Study. Completed NCT00993343 Phase 3 Sirolimus/tacrolimus;cyclosporine/methotrexate

Search NIH Clinical Center for Homologous Wasting Disease

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Daclizumab
Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
Muromonab-CD3
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Prednisone
PREDNISONE PWDR
Tacrolimus
Thalidomide

Genetic Tests for Homologous Wasting Disease

Anatomical Context for Homologous Wasting Disease

MalaCards organs/tissues related to Homologous Wasting Disease:

41
Bone, T Cells, Bone Marrow, Myeloid, Skin, Eye, Liver

Publications for Homologous Wasting Disease

Articles related to Homologous Wasting Disease:

(show top 50) (show all 2085)
# Title Authors PMID Year
1
Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS. 38
30532055 2019
2
Baseline predictors influencing the prognosis of invasive aspergillosis in adults. 38
31066092 2019
3
The Chronic Graft-vs.-Host Disease Failure-Free Survival (cGVHD-FFS) index. 38
31394265 2019
4
Iron deficiency anemia associated with extracorporeal photopheresis: A retrospective analysis. 38
31436854 2019
5
Modeling chronic Graft-vs-Host disease in MHC-matched mouse strains: genetics, graft composition and tissue targets. 38
31415899 2019
6
An automated mini buffy coat preparation method for use in mini extracorporeal photopheresis treatment of graft-vs-host-disease in a low body weight pediatric patient. 38
30829417 2019
7
Haploidentical hematopoietic stem cell transplantation in adults using the αβTCR/CD19-based depletion of G-CSF-mobilized peripheral blood progenitor cells. 38
31431717 2019
8
IFN-γ-tethered hydrogels enhance mesenchymal stem cell-based immunomodulation and promote tissue repair. 38
31401468 2019
9
Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation. 38
31431704 2019
10
In vitro PUVA treatment triggers calreticulin exposition and HMGB1 release by dying T lymphocytes in GVHD: New insights in extracorporeal photopheresis. 38
30860623 2019
11
Apheresis red blood cells associated with repeated hemolysis during blood priming of the Cellex Photopheresis System. 38
31403730 2019
12
Mononuclear cell collection for extracorporeal photopheresis by using the "off-line" system: A comparative study between COBE Spectra and Spectra Optia devices. 38
30549092 2019
13
Treatment rationale and design of a phase II study of narrow-band ultraviolet B phototherapy for cutaneous steroid-refractory acute graft-vs-host disease following allogenic stem-cell transplantation. 38
31305435 2019
14
Haploidentical donor transplants for severe aplastic anemia. 38
31202429 2019
15
Veto cells for safer nonmyeloablative haploidentical HSCT and CAR T cell therapy. 38
31202427 2019
16
Impact of HLA-DPB1 Matching on Outcome of Unrelated Transplant for Hematologic Malignant Diseases: A Systematic Review and Meta-analysis. 38
31399180 2019
17
Immune reconstitution after T-cell replete HLA-haploidentical transplantation. 38
31202434 2019
18
Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation. 38
30958904 2019
19
Decoding Skin Involvement in Chronic Graft-vs-Host Disease. 38
30994870 2019
20
Crowdsourcing to delineate skin affected by chronic graft-vs-host disease. 38
30786065 2019
21
Interrater Reliability of Clinical Grading Measures for Cutaneous Chronic Graft-vs-Host Disease. 38
30994873 2019
22
Psychological Considerations in Hematopoietic Stem Cell Transplantation. 38
31072626 2019
23
Lung clearance index for early detection of pulmonary complications after allo-HSCT in children. 38
31004401 2019
24
A Preliminary Investigation towards the Risk Stratification of Allogeneic Stem Cell Recipients with Respect to the Potential for Development of GVHD via Their Pre-Transplant Plasma Lipid and Metabolic Signature. 38
31349646 2019
25
Induction of acute graft vs. host disease in lymphopenic mice. 38
31248669 2019
26
Properties of FDA-approved small molecule protein kinase inhibitors. 38
30877063 2019
27
The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation. 38
31162830 2019
28
Sirolimus-associated pericardial effusion with cardiac tamponade and interstitial pneumonitis in a hematopoietic stem cell transplant recipient. 38
31012209 2019
29
Oral lichen planus: A disease or a spectrum of tissue reactions? Types, causes, diagnostic algorhythms, prognosis, management strategies. 38
31090143 2019
30
Acute graft-vs-host disease following liver transplantation. 38
31348462 2019
31
Phenotypical diversity of airway morphology in chronic lung graft vs. host disease after stem cell transplantation. 38
30723292 2019
32
Low incidence of HHV-6 reactivation in haploidentical hematopoietic stem cell transplantation with corticosteroid as graft-vs-host disease prophylaxis compared with cord blood transplantation. 38
30875143 2019
33
Solid organ transplantation after hematopoietic stem cell transplantation in childhood: A multicentric retrospective survey. 38
30586230 2019
34
Adjunctive fecal microbiota transplantation in supportive oncology: Emerging indications and considerations in immunocompromised patients. 38
30940601 2019
35
Accompanying editorial on paper Neutrophil Extracellular Traps (NETs) contribute to Pathological Changes of ocular Graft-vs.-Host Disease (oGVHD) Dry Eye: Implications for novel Biomarkers and Therapeutic Strategies by Seungwon An et al. 38
31226421 2019
36
Associations between febrile neutropenia-related parameters and the risk of acute GVHD or non-relapse mortality after allogeneic hematopoietic stem cell transplantation. 38
30171223 2019
37
Smoldering type adult T-cell leukemia/lymphoma effectively treated with mogamulizumab (anti-CC chemokine receptor 4 monoclonal antibody)-A case report. 38
31110745 2019
38
Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. 38
31089279 2019
39
Allogeneic CAR T cell therapies for leukemia. 38
30632623 2019
40
Neutropenic Enterocolitis in Critically Ill Patients: Spectrum of the Disease and Risk of Invasive Fungal Disease. 38
30741755 2019
41
Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. 38
30531955 2019
42
Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. 38
31097628 2019
43
Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis? 38
30720902 2019
44
Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study. 38
31065565 2019
45
High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease. 38
30108323 2019
46
Melanonychia striata: clarifying behind the Black Curtain. A review on clinical evaluation and management of the 21st century. 38
31006857 2019
47
Gene Polymorphism of Tacrolimus-Metabolizing Enzymes Associated With Impaired Absorption of Tacrolimus Following Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. 38
30979494 2019
48
Anti-thymocyte globulin's activity against acute myeloid leukemia stem cells. 38
30108326 2019
49
Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. 38
30637784 2019
50
Neutrophil extracellular traps (NETs) contribute to pathological changes of ocular graft-vs.-host disease (oGVHD) dry eye: Implications for novel biomarkers and therapeutic strategies. 38
30965123 2019

Variations for Homologous Wasting Disease

Expression for Homologous Wasting Disease

Search GEO for disease gene expression data for Homologous Wasting Disease.

Pathways for Homologous Wasting Disease

GO Terms for Homologous Wasting Disease

Sources for Homologous Wasting Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....